Archean Sciences
Champaign, Illinois, United StatesSee on the mapFounded 2026
- Brain-computer interfaces
- Neuroscience research tools
- Seed
Archean Sciences engineers living neural tissue for applications in human health and biohybrid computing. Its platform combines neural tissue with custom hardware and software to automate experiments, maintain culture health, and program neural activity.
- RaisedTotal raised
- $770K
- Aug 2026Latest priced round, Aug 2026
- Seed
- Investors
- 3
- Founded
- 2026
- Employees
- 2–10
reccy insights
Archean Sciences was founded in 2026 and is developing an autonomous brain-on-a-chip platform that combines living human neurons with custom hardware and software. A grant is listed on Apr 17, 2026, with TechNexus Venture Collaborative, Origin Ventures Group, and Illinois Ventures named as leads; no grant amount is specified. The company’s Seed financing is dated Aug 13, 2026, with structured funding data listing $385,000 and a broad group of named investors, including TechNexus Venture Collaborative, Origin Ventures Group, Sweet Spot Capital, Multimodal Ventures, and Illinois Ventures. A separate $385,000 SAFE offering is also dated that day. Hiring signals describe 150% quarter-over-quarter growth, from two to five employees, while the structured employee count is two. No product launch, partnership, award, or leadership-change announcements are included in the available company profile. The clearest milestones are therefore its 2026 financing activity and early team growth, rather than publicly described commercial deployments or clinical results.
Written by reccy's AI from company sites, press and funding records · updated Nov 2026
What makes Archean Sciences distinct
- 01Integrates living neural tissue with custom hardware and software in one platform.
- 02Automates neuroscience experiments and supports neural culture health and activity programming.
- 03Targets both neurological drug discovery and biohybrid computing applications.
- 04Combines neuroengineering, scientific operations, and neuroscience expertise.
Technology & products
- Autonomous brain-on-a-chip platform
An AI-powered biological platform that interfaces living human neurons with custom hardware and software to automate in vitro neuroscience experiments, maintain neural culture health, and program neural activity.
- Neural tissue platform integrated with custom hardware and software.
- Automated experimentation and neural culture health maintenance.
- Neural activity programming.
Funding
- SeedAug 2026$385KLed by TechNexus Venture Collaborative, Origin Ventures Group, Sweet Spot Capital, Multimodal Ventures, Automated Deal Investing Network, Illinois Ventures, Proximity Ventures, Refactor Capital, Builders VC, Wonder Ventures, E1 Ventures, Tusk Venture Partners, Proximity
- SAFE OfferingAug 2026$385KLed by Multimodal Ventures, Origin Ventures II Management, LLC
- GrantApr 2026TechNexus Venture Collaborative, Origin Ventures Group, Illinois Ventures
Investors13
- TechNexus Venture Collaborative
- Origin Ventures Group
- Illinois Ventures
- Sweet Spot Capital
- Multimodal Ventures
- Automated Deal Investing Network
- Origin Ventures II Management, LLC
Similar companies
About Archean Sciences
- Products
- Autonomous brain-on-a-chip platform
- Leadership
- Austin Ellis-MohrMattia Gazzola
- Focus areas
- NeuroTechnology, biotech, research tools, hardware, medical devices, biohybrid computing, neural tissue, neuroscience
- Headquarters
- Champaign, Illinois, United States
- Founded
- 2026
- Employees
- 2–10
- Status
- Active · private